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Introduction: About one-fifth of patients with resectable non-small
cell lung cancer (NSCLC) are unsuitable for surgical treatment.
Radiofrequency ablation offers an alternative minimally invasive
option. We report the result of an intention-to-treat study with
long-term follow-up.
Methods: From 2001 to 2009, we performed 80 percutaneous
radiofrequency ablations of 59 stage I NSCLC in 57 inoperable
patients. Two patients were treated for two separate lesions. The
study group consisted of 45 males and 12 females, with mean age of
74 years (range, 40–88 years). All patients had pathological evi-
dence of NSCLC, which was in stage IA in 44 cases and in stage IB
in the other 15 cases. The mean size of the lesions was 2.6 cm
(range, 1.1–5 cm). Fourteen lesions were retreated up to five times.
The procedure was always performed under local anesthesia and
conscious sedation. Most of the procedures were performed under
computed tomography guidance, with nine under ultrasonography
guidance.
Results: In all cases, the procedure was technically successful. No
mortality was recorded, and major morbidity consisted of four cases
of pneumothorax requiring pleural drainage. At a mean follow-up of
47 months, the complete response rate was 59.3% (stage Ia 65.9%,
stage Ib 40%, p  0.01), with a mean local recurrence interval of
25.9 months. Median overall survival and cancer-specific survival
were 33.4 and 41.4 months, respectively. Cancer-specific actuarial
survival was 89% at 1 year, 59% at 3 years, and 40% at 5 years.
Conclusions: Radiofrequency ablation treatment of early-stage
NSCLC seems to be a effective minimally invasive therapy even in
the long-term period, particularly for stage Ia tumors.
Key Words: NSCLC, Early stage, Radiofrequency ablation, Percu-
taneous thermal ablation, Minimally invasive treatment.
(J Thorac Oncol. 2011;6: 2044–2051)
Surgical resection remains the cornerstone of therapy forearly-stage non-small cell lung cancer (NSCLC). Lobec-
tomy with hilar and mediastinal lymphadenectomy is the
standard surgical treatment for stage I and II disease and
offers the best chance for cure. Five-year survival rates are
reported between 57 to 85% for stage I and 39 to 55% for
stage II disease.1,2 The extent of pulmonary resection required
to achieve complete eradication of the malignancy has been a
hotly debated issue. Recently, some studies evaluate the role
of sublobar resections such as segmentectomy for early-stage
NSCLC, showing functional advantage,3–6 but doubts about
disease control still persist.1 However, many patients with
resectable early-stage disease are unable to tolerate pulmo-
nary resection, even sublobar resection, because of compro-
mised cardiopulmonary functions or other comorbidities. El-
Sherif et al.1 estimate that more than 20% of patients who are
diagnosed with early-stage NSCLC do not undergo operation
because of comorbidity health factors. Traditionally, patients
deemed medically inoperable have been treated by external-
beam radiation. Even if this therapy generally increases
survival in patients with early-stage NSCLC, the results were
poor, with a mean survival of 20 months and a 5-year survival
rate of 12%.7,8
In this scenario, it is not surprising if we have been
witness to a strong drive to develop other nonsurgical local
therapies. On one hand, there has been an evolution of the
same radiation therapy which led to the stereotactic technique
with interesting preliminary results.9–11 On the other hand,
since the early 1990s, image-guided percutaneous ablation
procedures have been developed to treat solid tumors, both
primary and secondary, starting from that of the liver and
then being transferred also to the lung tumors.12–16 Today,
many authors describe percutaneous radiofrequency ablation
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(RFA) as a minimally invasive technique with promising
oncological results and a relative degree of safety for treat-
ment of NSCLC.17–21 But few data are available about its
efficacy with a reasonable follow-up. Herein, we report the
outcomes of a prospective single-center study in the RFA
treatment of stage I NSCLC.
MATERIALS AND METHODS
This study received approval from the local ethical
committee for human research care. The primary end points
of the study were technical success, safety, and complete
ablation (CA) of the target tumor (evaluated at a minimum
follow-up of 1 year). Secondary end points were overall and
cancer-specific survival.
Patients were required to sign a written informed con-
sent, after adequate explanation of risks and possible benefits
of the procedure.
Preoperative Assessment and Selection Criteria
All patients underwent preoperative assessment as for
major pulmonary resection: chest radiograph, computed to-
mography (CT) scan of the chest and upper abdomen, lung
function test, and cardiovascular evaluation. Additional ex-
ams (e.g., brain CT scan, bone scintigraphy, and positron
emission tomography [PET]) were used in selected cases,
when clinical/radiological criteria raised the suspect of distant
metastases. Patients with mediastinal nodes greater than 1 cm
in short axis diameter on CT scan underwent transbronchial
needle aspiration and/or PET scan to exclude N2 disease.
The first selection criteria was a contraindication: con-
traindication to surgical treatment. A thoracic surgeon, to-
gether with an experienced anesthesiologist, evaluated the
patients as not suitable for lung resection. Main contraindi-
cations to surgery were presence of significant comorbidity
and poor lung function that makes the patient unable to
tolerate even a limited lung resection. Comorbidity was
evaluated prospectively according to the Adult Comorbidity
Evaluation-27 (ACE-27) scoring system. Moreover, three
patients refused surgery. Other main selection criteria were
lesions 5 cm; a distance from large vessels and airways
more than 1 cm; preoperative pathological proof of malig-
nancy; and a platelet count greater than 50  103/l.
Devices and Technique
We used a radiofrequency generator able to provide
monopolar energy to perform coagulation and ablation of soft
tissue (RITA Model 1500 and 1500X, AngioDynamics,
Latham, NY). This is an automatic device with a maximum
power output of 150 to 250 W operating at 460 MHz. The
generator has a display where temperatures, impedance, and
power are continuously monitored. The energy was trans-
ferred into the lesion by a deployable array (StarBurst XL,
AngioDynamics). It consists of a 14-gauge needle cannula
with nine deployable electrodes that open flower-like up to 5
cm. Five electrodes have a thermocouple on the tip which
allows continuous measurement of treatment temperature.
Two grounding pads were applied to each shaved leg to
ground the current and to reduce risks of heat injuries to the
skin.
All the procedures were performed with the patients
under conscious sedation (usually achieved with administra-
tion of ketorolac 0.5–0.8 mg/kg, propofol 1–2 mg/kg/h, and
remifentanil 0.1 mg/kg/min) and local anesthesia (subcutane-
ous 1% lidocaine). Vital signs of the patient were noninva-
sively monitored continuously. We used CT guidance in the
most of cases while, more recently, lesions in contact with
parietal pleura underwent RFA by ultrasonography guidance.
In all cases, the target temperature was 90°C. It was main-
tained, according to the protocol, for a time which ranged
from 15 to 27 minutes according to the size of the tumor,
which also determined the deployment of the electrodes
(Table 1). These electrodes were deployed gradually, starting
from 2 cm and then 1 cm for each step. Since 2007, we used
a new deployable array (StarBurst Talon, AngioDynamics)
with a perfusion system (Intelliflow pump, AngioDynamics)
that operates at 105°C, reducing the time at target tempera-
ture to 5 to 9 minutes, again according to the size of the tumor
(Table 1). In all cases, when technically possible, the objec-
tive of the lung RFA protocol was to encompass the tumor
with an ablation zone around the tumor of at least 1 cm
thickness. At the end of the procedure, after the automatic
cooling down of the radiofrequency system, the expandable
tines were retracted and the generator shifted to “track abla-
tion mode” which allows ablation of the pathway from the
tumor to the subcutaneous tissue to prevent bleeding or tumor
cell dissemination. After the procedure, all patients were
transferred to the recovery room for a 24-hour observation
period. Then, after a chest radiograph to exclude complica-
tions, they were discharged.
Follow-Up and Evaluation Criteria
Radiological follow-up included contrast-enhanced CT
at 1, 3, and 6 months and then at 6-month intervals. CT scans
were evaluated by two physicians, the same who performed
the procedure and another experienced thoracic surgeon or
radiologist. First evaluation was done just after RFA with a
postprocedural CT enhanced with contrast material. Techni-
cal success was defined as correct placement of the ablation
device into all target tumors with completion of the planned
ablation protocol (maintenance of the target temperature for
the required time according to tumor size).
The safety assessment included identification of treat-
ment-related complications and changes in pulmonary func-
tion. Pulmonary function testing, obtained before and after
RFA, included measurement of forced expiratory volume in
the first second (FEV1), FEV1% of that predicted, forced
vital capacity (FVC), and FVC percentage of that predicted.
TABLE 1. RFA Protocols According to the Device and the
Size of the Lesion
Tumor
Diameter
Electrodes Deployment/Time at
Target Temperature
StarBurst XL StarBurst Talon
2 cm 3 cm/15 min 3 cm/5 min
2–3 cm 4 cm/20 min 3.5 cm/7 min
3 cm 5 cm/27 min 4 cm/9 min
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 Long-Term Results of Radiofrequency Ablation Treatment
Copyright © 2011 by the International Association for the Study of Lung Cancer 2045
Treatment-related complications were those occurring within
30 days from treatment. Complications were assessed on a
per-procedure basis. Minor complications were defined as
those resulting in no sequelae or needing nominal treatment
or a short hospital stay for observation. Major complications
were defined as those resulting in readmission to the hospital
for treatment, an unplanned increase in the level of care,
extended hospitalization, permanent adverse sequelae, or
death. Assessment of target tumor response was based on CT
analysis of lesion size, lesion geometry, and lesion enhance-
ment. Because the aim of RFA was to produce a volume of
coagulation necrosis exceeding that of the native tumor, the
1-month follow-up CT scan (in which the high-density area
representing the ablation zone was usually larger than the
native tumor) was taken as a term of reference. Target tumors
showing at least a 30% decrease in longest diameter com-
pared with the diameter measured at 1-month CT, no evi-
dence of tumor growth from the zone of ablation, and no
evidence of contrast enhancement were assumed to have
undergone CA. The threshold of 30% is consistent with the
Response Evaluation Criteria in Solid Tumors (RECIST) and
was aimed at preventing overestimation of response due to
measurement variability.22 By contrast, target tumors show-
ing with at least a 20% increase in longest diameter in any of
the follow-up CT studies (as per RECIST, taking as reference
the smallest diameter measured at any time point), evidence
of tumor growth from the zone of ablation, or intratumoral
contrast uptake (equal/greater than preoperative, however
greater than 25 HU) were assumed to have undergone incom-
plete ablation. In some cases, a PET scan was used to better
assess recurrence, or lack of recurrence, of the lesion.
Statistical Analysis
Descriptive statistics for the series were generated with
STATISTICA software (StatSoft, Inc., Tulsa, OK; version 6.0
for Windows). Comparisons of percentages and mean values
were performed by using Student t test. Kaplan-Meier with
log-rank analysis was used to calculate overall survival (OS),
cancer-related survival (C-RS), and disease-free interval (DFI)
and to compare patients. A value of p less than 0.05 was
considered to indicate a statistically significant difference.
RESULTS
In the period 2001–2008, we performed more than 150
RFA of lung tumors. In 80 cases, it was for 59 stage I NSCLC
in 57 patients. Fourteen patients were treated up to five times
for the same lesion because of persistence or recurrence of the
disease. Interval between ablations was 3 months on average
(range, 1–12 months). Two patients were treated for two
different lesions (one synchronous and one metachronous),
according to Martini and Melamed criteria.23 There were 45
males and 12 females in the study group. The mean age was
74 years (range, 40–88 years), and the mean lesion size was
2.6 cm (range, 1.1–5 cm). Forty-four lesions were in stage Ia
and 15 in stage Ib. All lesions were pathologically proven: 29
adenocarcinomas, 15 squamous cell carcinomas, and 15 cy-
tologically proven NSCLC. ACE-27 score is reported in
Table 2.
Twenty patients who had a metachronous primary
NSCLC, according to Martini and Melamed criteria, previ-
ously underwent pulmonary resection: 17 lobectomies, 1
bilobectomy, 1 pneumonectomy, and 1 wedge resection. One
patient previously underwent combined chemoradiotherapy
for clinically inoperable stage Ib NSCLC before performing
RFA of the residual tumor. Thirty-six patients were not
previously treated before RFA.
Seventy-one RFAs were performed under CT guidance.
In nine cases of lesion in contact with the parietal pleura,
RFA by ultrasonography guidance was preferred. From 2001
to 2006, the mean time of the entire procedure was 39
minutes, which included time to hit the lesion (17 minutes on
average) and time of ablation (22 minutes on average). Since
2007, when we started to use the new internally cooled
deployable array (Talon Semi-Flex), the mean time of the
procedure decreased to 20 minutes. The mean postprocedural
hospital stay was 1.3 days (range, 1–5 days).
The procedure was technically successful in all patients
who entered the study, and it was generally well tolerated. No
mortality was recorded, while major complications were
observed in 5% of cases: four pneumothorax requiring pleural
drainage and longer hospital stay. Minor complications oc-
curred in 20% of cases: five patients, with lesions next to the
pleural surface, experienced pain related to RFA, which
required the deepening of sedation, which, however, cleared
up a few minutes after the end of the procedure; five cases of
small pneumothorax treated with observation; three cases of
tiny pleural effusion; two minor hemoptysis; and one hema-
TABLE 2. Background of the Patients
Patient Characteristics n  57
Age, mean (range), yr 74 (40–88)
Gender (male/female) 45/12
Previous lung cancer (N) 20
Comorbidity score (ACE-27)
1  mild 3
2  moderate 11
3  severe 43
Tumor Characteristics n  59
Maximum tumor size,a mean (range), cm 2.6 (1.1–5)
Stageb
Ia 44
Ib 15
T factorb
T1a 25
T1b 19
T2a 15
Histology
Adenocarcinoma 29
Squamous cell carcinoma 15
NSCLC 15
a At computed tomography scan.
b According to the new 7th Edition TNM Staging System.
ACE-27, Adult Comorbidity Evaluation-27 scoring system; NSCLC, non-small cell
lung cancer.
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toma of the chest wall. There was no increase of toxicity in
patients who underwent repeated RFA treatments due to local
persistence/relapse of the tumor (only one case of pneumo-
thorax recorded in these patients).
Pulmonary function tests were completed at 6 months
after RFA in 27 patients. They did not show any significant
worsening in FEV1, FEV1% predicted, FVC, or FVC per-
centage predicted in any follow-up visits compared with
baseline values (Table 3). The slight decrease noted in these
values was neither statistically significant nor clinically rel-
evant, and it could be related to the progressive development
of the underlying chronic pulmonary disease.
At the end of the study (December 2009), 23 patients
(40%) were still alive, and among those patients, 20 (87%)
were disease-free (DF). Ten patients who died were DF.
Progression of the disease occurred in 29 tumors (49%): 13
for local recurrence (LR). In case of multiple RFA of the
same tumor, LR was calculated at the end of the last treat-
ment, 11 LR associated to distant (mediastinal or other sites)
recurrence (DR), and only 5 DR. Most of these patients
underwent some adjuvant therapy (CT and/or RT). Stereo-
tactic radiotherapy was successful to complete the ablation in
four cases with LR.
Response Rates and Survival Analysis
At a mean follow-up of 47 months (median 45.5; range,
12–82), the overall CA rate was 59% (35/59 nodules). Sig-
nificantly better results were reported for stage Ia than for
stage Ib, with a CA rate of 66 and 40% (p  0.01), respec-
tively, and a mean local progression-free interval of 30.2 and
13.4 months (p  0.009), respectively. By Kaplan-Meier
analysis, median DFI was 39 months, again better for stage Ia
than for stage Ib (p  0.01) (Figures 1 and 2). Median OS
was 33.4 months, while median C-RS was 41.4 months
(Figures 3 and 4). Even for these parameters, better results,
which were statistically significant, were achieved for stage
Ia than for stage Ib lesions: median OS was 35 and 20 months
(p  0.02), respectively, while median C-RS was 52 and 25
months (p  0.004), respectively (Figure 5). We did not find
any significant difference in OS and C-RS comparing other
parameters such as age, histology, and previous lung cancer
(yes versus no). The overall cumulative proportion surviving
was 83% at 1 year, 40% at 3 years, and 25% at 5 years, while
that which was cancer-related was 89, 59, and 40%, respec-
tively, which increased again to values of 95, 71, and 52%,
respectively, for stage Ia disease.
DISCUSSION
Despite the effort to minimize surgical impact, even
with less-invasive surgical approaches (e.g., muscle-sparing
thoracotomy, video-assisted thoracic surgery), it is estimated
that up to one-fifth of patients with early-stage NSCLC are
unsuitable for surgical treatment due to comorbidities.1 These
patients were usually initiated to radiotherapy, which showed
poor, but better, results compared with those patients who had
no therapy.7,8 McGarry et al.24 reported, in a study on early-
stage medically inoperable lung cancer, a median survival
time of 14.2 months for patients who underwent observation-
only management with respect to 19.9 months for those
patients treated with radiotherapy alone (p  0.0005). In
FIGURE 1. Kaplan-Meier curve representing
disease-free survival.
TABLE 3. Mean Value (Range) of the Lung Function Tests
Before and After RFA in 27 Patients
Baseline At 3 mo At 6 mo P
FVC
(liters)
2.39 (1.33–4.07) 2.33 (1.22–3.83) 2.30 (1.19–4.02) NS
FVC %
predicted
68.5 (54–101) 66.9 (44–93) 66.1 (46–97) NS
FEV1
(liters)
1.51 (0.65–3.12) 1.44 (0.66–2.97) 1.56 (0.69–3.21) NS
FEV1%
predicted
61.2 (28–111) 59.3 (27–100) 60.5 (33–102) NS
FVC, forced vital capacity; FEV1, forced expiratory volume in the first 1 s.
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another study, Wisnivesky et al.25 analyzing the Surveillance,
Epidemiology, and End Results registry showed that patients
with stage I NSCLC who received radiotherapy had signifi-
cantly better median survival time when compared with
untreated patients (21 versus 14 months, p  0.0001), even if
the 5-year survival rate was not significantly different (15
versus 14%).
So we can comprehend the efforts of the last years to
develop minimally invasive procedures to give an alternative
of local treatment in these unlucky patients. RFA has been
proposed as a viable option for the treatment of pulmonary
malignancies. Experimental studies in animal tumor models
have confirmed the effectiveness of RFA in the destruction of
lung parenchyma and experimentally induced pulmonary
malignancies.13,26,27 Clinical investigations have shown the
safety of percutaneous CT-guided RFA procedures in human
beings, even in single-lung patients.28 Since 2004, Steinke et
al.,29 in an international study survey, collected the data from
almost 500 patients and confirmed RFA as a minimally
invasive tool for local disease control, with negligible mor-
tality, low morbidity, short hospital stay, and a gain in quality
of life. At the same time, the biological effects of RFA in the
lung and its neoplasms were assessed in two independent
clinical studies, demonstrating its efficacy in killing the tumor
cells and in preserving the surrounding pulmonary paren-
chyma.30,31 Today several authors report excellent results in
terms of CA rates,18–21 which range from 60 to 69%. It is now
clear that it depends mainly on the size of the tumor, better
for lesions smaller than 3 cm and not completely satisfactory
for lesions greater than 5 cm. Our prospective intention-to-
treat trial confirms the safety, feasibility, and effectiveness of
the procedure. We reported a technical success of 100%, no
FIGURE 2. Kaplan-Meier curves of disease-
free survival by stage (Ia versus Ib).
FIGURE 3. Kaplan-Meier curve of overall
survival.
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mortality, a low morbidity rate, and no significant impairment
of pulmonary function. We also obtained a CA rate of almost
60%, which was, in our experience too, significantly higher in
lesions smaller than 3 cm (66%) but not affected by tumor
histology. This seems worse than other results reported in the
literature but justified by the long minimum and mean fol-
low-up periods of our series, which were 12 and 47 months,
respectively. One of the limitations of the previous studies, in
fact, was the follow-up period, which might not have been
sufficiently long to detect late tumor recurrences. Moreover,
in our study, we excluded patients without pathological proof
of malignancy, which could alter oncological results. Despite
this, our trial shows overall and actuarial survivals that are
comparable to those reported by other authors with shorter
follow-up periods (Table 4). This seems to confirm that
oncological outcomes achievable for early-stage disease per-
sist even in the long term. In addition, in our study, these
results seem not impaired, or even better, if repeated attempts
to ablate the lesion are necessary. This could be explained
with the larger ablation area obtained by the sum of the RFA
attempts.
Still, a reliable comparison of survival curves obtained
with RFA with those achieved with other treatments is not
possible. Overall survival of patients treated by RFA is
greatly affected by the recruitment of patients with severely
impaired pulmonary function and/or considerable comorbidi-
ties. This is probably the reason why, in our series and also in
those reported in the literature, a substantial difference be-
tween overall survival and cancer-specific survival was
noted, because most deaths were not related to cancer pro-
FIGURE 4. Kaplan-Meier curve of cancer-re-
lated survival.
FIGURE 5. Kaplan-Meier curves of cancer-
related survival by stage (Ia versus Ib).
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gression. Nevertheless, the 40% 5-year C-RS obtained with
stage I NSCLC is promising and in agreement with recent
published findings (Table 4). These results can compare well
with reported outcomes of external-beam radiation therapy,
while recently stereotactic body radiation therapy showed an
even better local control rate in this patient population;
however, the influence that these differences have on overall
survival is unclear.10,11
To better understand the clinical impact of RFA on
NSCLC, the comparison with surgically treated octogenari-
ans, whose overall 5-year survival is reported between 34 and
66% (Table 5), would be useful. These patients, despite a
careful preoperative selection, are to be considered high-risk
patients, thus with a high rate of deaths not related to cancer,
just as happens for RFA patients. Surgical treatment still
remains the best option even in these elderly patients, al-
though, with respect to RFA, we have to take into account a
higher mortality and morbidity rate.
Certainly, our study does have some limitations. The
first one could be the limited number of treated patients.
Second, despite the strict criteria adopted for the definition of
response, effectiveness of the procedure was confirmed by
radiological means alone. Moreover, the survival benefit can
be favorably comparable only with lack of treatment and,
most likely, with standard external beam radiation. So, noth-
ing definitive can be ascertained without a randomized con-
trolled trial comparing RFA with new minimally invasive and
standard treatment options, which would now be necessary to
prove the clinical benefit of this procedure.
CONCLUSIONS
Although this study has assessed, together with feasi-
bility and safety, the efficacy of RFA treatment of NSCLC
even in the long term, it must be considered a compromise
procedure with respect to surgical resection for early-stage
NSCLC. In fact, together with stereotactic body radiation
therapy, which recently showed even better results, it is to
emphasize that RFA is a kind of local treatment of the tumor,
and, at the best, in future, it could be speculated on this
procedures to compete with nonanatomical limited lung re-
sections.
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